4.6 Article

Associations between workability and patient-reported physical, psychological and social outcomes in breast cancer survivors: a cross-sectional study

期刊

SUPPORTIVE CARE IN CANCER
卷 26, 期 8, 页码 2815-2824

出版社

SPRINGER
DOI: 10.1007/s00520-018-4132-2

关键词

Breast neoplasms; Patient-reported outcome measures; Workability; employment

资金

  1. National University Hospital, Singapore
  2. Clinician Scientist Award
  3. National Medical Research Council [R-608-000-093-511]
  4. Asian Breast Cancer Research Fund [N-176-000-023-091]

向作者/读者索取更多资源

Purpose Workability is of increasing importance especially in Asia given the increasing incidence rates and young age of onset of breast cancer. This study explores the determinants of employment and suboptimal workability. And evaluate the association between workability and patient-reported physical, psychological, and social outcomes. Methods In a hospital-based cross-sectional study, 327 breast cancer survivors, < 65 years of age and > 1 year post-diagnosis were recruited. Employed survivors filled out the workability index, which measures a person's capacity to meet work demands in relation to current health status. The EORTC-QLQ-C30, EORTC-QLQ-BR23, hospital anxiety and depression scale, multidimensional fatigue inventory, and brief pain index were administered. Fisher's exact test and Kruskal-Wallis test were used to test for associations of workability and employment status with demographic, clinical characteristics, and patient-reported outcomes. Linear models with standardised scores for patient-reported outcomes were fitted to study the associations of workability with patient-reported outcomes. Results Of the 327 survivors, < 65 years of age (working age), 140 (43%) were in full-time and 34 (10%) in part-time employment. Employed survivors were younger at time of diagnosis and at time of survey. Employment status was not associated with time since diagnosis, ethnicity, or clinical characteristics. Suboptimal workability was present in 37% of employed survivors of the working age, and more common in jobs that include physical work activities. Higher level of depression, financial difficulty and physical fatigue, more breast symptoms, and poorer global health status were independently associated with poorer workability. Conclusions Lower employment and reduced workability in breast cancer survivors is common, and reduced workability is associated with higher levels of depression, financial difficulty and physical fatigue, more breast symptoms, and poorer global health status. Longitudinal research on psychosocial support with workability in Asia may find tailored approach to improve or maintain workability in employed breast cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer

Kritika Yadav, Joline Lim, Joan Choo, Samuel Guan Wei Ow, Andrea Wong, Matilda Lee, Ching Wan Chan, Mikael Hartman, Siew Eng Lim, Natalie Ngoi, Siau Wei Tang, Yvonne Ang, Gloria Chan, Wan Qin Chong, Hon Lyn Tan, Sing Huang Tan, Boon Cher Goh, Soo Chin Lee

Summary: The study compared the anti-angiogenic effects of Sunitinib and Bevacizumab in breast cancer patients, with results showing that Sunitinib significantly increased tumor vessel normalization and decreased lymphatic vessel density, leading to reduced tumor proliferation when used in combination with chemotherapy.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Rheumatology

Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus

Sofie A. M. Gernaat, Julia F. Simard, Anna-Karin Wikstrom, Elisabet Svenungsson, Elizabeth V. Arkema

Summary: The study found a risk association between systemic lupus erythematosus (SLE) and gestational diabetes mellitus (GDM), with women with SLE being more likely to develop GDM during pregnancy compared to general population controls.

JOURNAL OF RHEUMATOLOGY (2022)

Article Oncology

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors

Matilda Xinwei Lee, Andrea L. A. Wong, Samuel Ow, Raghav Sundar, David S. P. Tan, Ross A. Soo, Cheng Ean Chee, Joline S. J. Lim, Wei Peng Yong, Siew Eng Lim, Boon Cher Goh, Lingzhi Wang, Soo Chin Lee

Summary: Varlitinib is a potent pan-HER inhibitor with demonstrated activity in various cancers. The study confirmed the safety and efficacy of combining varlitinib with chemotherapy, with the recommended phase II dose being 300 mg twice daily. Subcutaneous trastuzumab can be safely added to this combination for further evaluation in HER2+ breast cancer.

TARGETED ONCOLOGY (2022)

Review Oncology

Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis

Aaron Shengting Mai, Ainsley Ryan Yan Bin Lee, Ryan Yong Kiat Tay, Lauren Shapiro, Astha Thakkar, Balazs Halmos, Albert Grinshpun, Yair Herishanu, Ohad Benjamini, Tamar Tadmor, Rachna T. Shroff, Bonnie J. LaFleur, Deepta Bhattacharya, Siyu Peng, Jeremy Tey, Soo Chin Lee, Louis Yi Ann Chai, Yu Yang Soon, Raghav Sundar, Matilda Xinwei Lee

Summary: This study evaluates the need for booster doses in cancer patients receiving COVID-19 vaccination to improve seroconversion rates. The results show lower seroconversion rates in hematological cancer patients compared to solid cancer patients. Individual patient data analysis also identifies an association between increased duration between the second and third dose, age of the patient, and cancer type with meaningful rise in antibody titres.

EUROPEAN JOURNAL OF CANCER (2022)

Review Medicine, General & Internal

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Louis Yi Ann Chai, Soo Chin Lee, Matilda Xinwei Lee, Mark Dhinesh Muthiah, Sen Hee Tay, Chong Boon Teo, Benjamin Kye Jyn Tan, Yiong Huak Chan, Raghav Sundar, Yu Yang Soon

Summary: This systematic review and meta-analysis compared the efficacy of covid-19 vaccines between immunocompromised and immunocompetent individuals. The results showed that immunocompromised patients, especially organ transplant recipients, had significantly lower rates of seroconversion after covid-19 vaccination. A second dose of the vaccine consistently improved seroconversion in all patient groups, although the improvement was smaller for organ transplant recipients. Targeted interventions, including a third dose (booster) of the vaccine, should be performed for immunocompromised patients.

BMJ-BRITISH MEDICAL JOURNAL (2022)

Article Multidisciplinary Sciences

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+breast cancer

Li-Teng Ong, Wee Chyan Lee, Shijun Ma, Gokce Oguz, Zhitong Niu, Yi Bao, Mubaraka Yusuf, Puay Leng Lee, Jian Yuan Goh, Panpan Wang, Kylie Su Mei Yong, Qingfeng Chen, Wenyu Wang, Adaikalavan Ramasamy, Dave S. B. Hoon, Henrik J. Ditzel, Ern Yu Tan, Soo Chin Lee, Qiang Yu

Summary: In this study, we discovered that IF‑β is highly expressed in HER2(+) breast cancer and inhibits the malignant characteristics of cancer cells by regulating the AKT signaling pathway and XBP1 activation.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Medicine, Research & Experimental

FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites

Win Lwin Thuya, Li Ren Kong, Nicholas L. Syn, Ling -Wen Ding, Esther Sok Hwee Cheow, Regina Tong Xin Wong, Tingting Wang, Robby Miguel Wen-Jing Goh, Hongyan Song, Migara K. Jayasinghe, Minh T. N. Le, Jian Cheng Hu, Wei-Peng Yong, Soo-Chin Lee, Andrea Li-Ann Wong, Gautam Sethi, Huynh The Hung, Paul Chi-Lui Ho, Jean-Paul Thiery, Siu Kwan Sze, Tiannan Guo, Ross A. Soo, Henry Yang, Yaw Chyn Lim, Lingzhi Wang, Boon-Cher Goh

Summary: This study reveals that the cargo protein FAM3C carried by tumor-released extracellular vesicles (EVs) can enhance the growth and metastatic potential of lung cancer cells. FAM3C interacts with RalA protein to activate the Src/Stat3 signaling pathway, promoting oncogenicity. This finding provides a new target for lung cancer therapy.

THERANOSTICS (2023)

Article Oncology

Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials

Jerold Loh, Jiaxuan Wu, Jenny Chieng, Aurora Chan, Wei-Peng Yong, Raghav Sundar, Soo-Chin Lee, Andrea Wong, Joline S. J. Lim, David S. P. Tan, Ross Soo, Boon-Cher Goh, Bee-Choo Tai, Cheng E. Chee

Summary: Patient selection is crucial in Phase I studies, particularly in heavily pre-treated patients where prognosis estimation is challenging. Existing prognostic models like the Royal Marsden Hospital (RMH) score or the neutrophil-lymphocyte ratio (NLR) have not been validated in current novel therapies or in the Asian Phase I population.

BRITISH JOURNAL OF CANCER (2023)

Correction Genetics & Heredity

Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (vol 55, pg 89, 2023)

Ceres Fernandez-Rozadilla, Maria Timofeeva, Zhishan Chen, Philip Law, Minta Thomas, Stephanie Schmit, Virginia Diez-Obrero, Li Hsu, Juan Fernandez-Tajes, Claire Palles, Kitty Sherwood, Sarah Briggs, Victoria Svinti, Kevin Donnelly, Susan Farrington, James Blackmur, Peter Vaughan-Shaw, Xiao-ou Shu, Jirong Long, Qiuyin Cai, Xingyi Guo, Yingchang Lu, Peter Broderick, James Studd, Jeroen Huyghe, Tabitha Harrison, David Conti, Christopher Dampier, Mathew Devall, Fredrick Schumacher, Marilena Melas, Gad Rennert, Mireia Obon-Santacana, Vicente Martin-Sanchez, Ferran Moratalla-Navarro, Jae Hwan Oh, Jeongseon Kim, Sun Ha Jee, Keum Ji Jung, Sun-Seog Kweon, Min-Ho Shin, Aesun Shin, Yoon-Ok Ahn, Dong-Hyun Kim, Isao Oze, Wanqing Wen, Keitaro Matsuo, Koichi Matsuda, Chizu Tanikawa, Zefang Ren, Yu-Tang Gao, Wei-Hua Jia, John Hopper, Mark Jenkins, Aung Ko Win, Rish Pai, Jane Figueiredo, Robert Haile, Steven Gallinger, Michael Woods, Polly Newcomb, David Duggan, Jeremy Cheadle, Richard Kaplan, Timothy Maughan, Rachel Kerr, David Kerr, Iva Kirac, Jan Bohm, Lukka-Pekka Mecklin, Pekka Jousilahti, Paul Knekt, Lauri Aaltonen, Harri Rissanen, Eero Pukkala, Johan Eriksson, Tatiana Cajuso, Ulrika Hanninen, Johanna Kondelin, Kimmo Palin, Tomas Tanskanen, Laura Renkonen-Sinisalo, Brent Zanke, Satu Mannisto, Demetrius Albanes, Stephanie Weinstein, Edward Ruiz-Narvaez, Julie Palmer, Daniel Buchanan, Elizabeth Platz, Kala Visvanathan, Cornelia Ulrich, Erin Siegel, Stefanie Brezina, Andrea Gsur, Peter Campbell, Jenny Chang-Claude, Michael Hoffmeister, Hermann Brenner, Martha Slattery, John Potter, Konstantinos Tsilidis, Matthias Schulze, Marc Gunter, Neil Murphy, Antoni Castells, Sergi Castellvi-Bel, Leticia Moreira, Volker Arndt, Anna Shcherbina, Mariana Stern, Bens Pardamean, Timothy Bishop, Graham Giles, Melissa Southey, Gregory Idos, Kevin McDonnell, Zomoroda Abu-Ful, Joel Greenson, Katerina Shulman, Flavio Lejbkowicz, Kenneth Offit, Yu-Ru Su, Robert Steinfelder, Temitope Keku, Bethany van Guelpen, Thomas Hudson, Heather Hampel, Rachel Pearlman, Sonja Berndt, Richard Hayes, Marie Elena Martinez, Sushma Thomas, Douglas Corley, Paul Pharoah, Susanna Larsson, Yun Yen, Heinz-Josef Lenz, Emily White, Li Li, Kimberly Doheny, Elizabeth Pugh, Tameka Shelford, Andrew Chan, Marcia Cruz-Correa, Annika Lindblom, David Hunter, Amit Joshi, Clemens Schafmayer, Peter Scacheri, Anshul Kundaje, Deborah Nickerson, Robert Schoen, Jochen Hampe, Zsofia Stadler, Pavel Vodicka, Ludmila Vodickova, Veronika Vymetalkova, Nickolas Papadopoulos, Chistopher Edlund, William Gauderman, Duncan Thomas, David Shibata, Amanda Toland, Sanford Markowitz, Andre Kim, Stephen Chanock, Franzel van Duijnhoven, Edith Feskens, Lori Sakoda, Manuela Gago-Dominguez, Alicja Wolk, Alessio Naccarati, Barbara Pardini, Liesel FitzGerald, Soo Chin Lee, Shuji Ogino, Stephanie Bien, Charles Kooperberg, Christopher Li, Yi Lin, Ross Prentice, Conghui Qu, Stephane Bezieau, Catherine Tangen, Elaine Mardis, Taiki Yamaji, Norie Sawada, Motoki Iwasaki, Christopher Haiman, Loic Le Marchand, Anna Wu, Chenxu Qu, Caroline McNeil, Gerhard Coetzee, Caroline Hayward, Ian Deary, Sarah Harris, Evropi Theodoratou, Stuart Reid, Marion Walker, Li Yin Ooi, Victor Moreno, Graham Casey, Stephen Gruber, Ian Tomlinson, Wei Zheng, Malcolm Dunlop, Richard Houlston, Ulrike Peters

NATURE GENETICS (2023)

Article Oncology

A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies

Cheng E. Chee, Melissa Ooi, Soo-Chin Lee, Raghav Sundar, Valerie Heong, Wei-Peng Yong, Chin Hin Ng, Andrea Wong, Joline S. J. Lim, David S. P. Tan, Ross Soo, Joshua T. C. Tan, Song Yang, Min Thura, Abdul Qader Al-Aidaroos, Wee Joo Chng, Qi Zeng, Boon-Cher Goh

Summary: This study aims to evaluate the safety and efficacy of PRL3-zumab in patients with advanced solid tumors and hematological malignancies. The results show that PRL3-zumab is safe and tolerable, with stable disease observed in some solid tumor patients.

TARGETED ONCOLOGY (2023)

Meeting Abstract Oncology

A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR).

Gwo Fuang Ho, Soo-Chin Lee, Joanna Lim, Anita Zarina Bustam, Siew Eng Lim, Marniza Saad, Samuel Guan Wei Ow, Natalie Ngoi, Nur Fadhlina Abdul Satar, Rozita Abdul Malik, Adlinda Alip, Kian Boon Law, Yok Yong Toh, Jia Wern Pan, Soo Hwang Teo

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors

Joan R. E. Choo, Yi-Hua Jan, Samuel G. W. Ow, Andrea Wong, Matilda Xinwei Lee, Natalie Ngoi, Kritika Yadav, Joline S. J. Lim, Siew Eng Lim, Ching Wan Chan, Mikael Hartman, Siau Wei Tang, Boon Cher Goh, Hon Lyn Tan, Wan Qin Chong, Ang Li En Yvonne, Gloria H. J. Chan, Shu-Jen Chen, Kien Thiam Tan, Soo Chin Lee

Summary: Serial molecular profiling can identify early therapy-induced genomic alterations in HER2-negative breast cancer patients, which may guide the selection of targeted therapies in patients who progress after standard chemotherapy.

TARGETED ONCOLOGY (2022)

Article Oncology

Clinical characteristics and genetic testing outcome of suspected hereditary peripheral nerve sheath tumours in a tertiary cancer institution in Singapore

Jerold Loh, Pei Yi Ong, Denise Li Meng Goh, Mark E. Puhaindran, Balamurugan A. Vellayappan, Samuel Guan Wei Ow, Gloria Chan, Soo-Chin Lee

Summary: Hereditary peripheral nerve sheath tumors (PNSTs) are uncommon in the general population. Through analyzing the clinical characteristics and genetic testing results, NF1 is found to be the most common PNST, and LZTR1 variants may be the underlying cause in Asian patients with multiple schwannomatosis.

HEREDITARY CANCER IN CLINICAL PRACTICE (2022)

Article Oncology

A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies

Jingshan Ho, Valerie Heong, Wei Peng Yong, Ross Soo, Cheng Ean Chee, Andrea Wong, Raghav Sundar, Yee Liang Thian, Anil Gopinathan, Mei Yan Pang, Priscillia Koe, Santhiay Nathan Jeraj, Phyu Pyar Soe, Mu Yar Soe, Tiffany Tang, Matthew C. H. Ng, David W. M. Tai, Tira J. Y. Tan, Hongmei Xu, Hua Chang, Yosef Landesman, Jatin Shah, Sharon Shacham, Soo Chin Lee, Daniel S. W. Tan, Boon Cher Goh, David S. P. Tan

Summary: This phase 1 study evaluated the tolerability and recommended dose of Selinexor in Asian patients with advanced malignancies. The results showed that a dose of 40 mg/m^2 given twice every 3 weeks was the most tolerable for Asian patients. Selinexor had rapid oral absorption and no PK accumulation.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)

Article Psychology, Clinical

Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy

Eng Hooi Tan, Andrea Li Ann Wong, Chuan Chien Tan, Patrick Wong, Sing Huang Tan, Li En Yvonne Ang, Siew Eng Lim, Wan Qin Chong, Jingshan Ho, Soo Chin Lee, Bee Choo Tai

Summary: The study validated the Beliefs about Medicines Questionnaire (BMQ) and Adherence Starts with Knowledge (ASK-12) questionnaire for use in a Singapore population with early stage breast cancer. The new factor structure obtained from exploratory factor analysis improved the internal consistency of BMQ-General and ASK-12 Behaviour scale. Further studies are required to confirm these factor structures.

JOURNAL OF HEALTH PSYCHOLOGY (2022)

暂无数据